CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 71 enrolled
Drug / intervention
Anastrozoledrug
Likely dose
Anastrozole 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01016665
NCT01016665N/ACompleted
CompareCT.gov

Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study

Federal University of São Paulo·interventional·Posted Nov 19, 2009·Updated Nov 19, 2009

In Brief

A clinical study evaluating Anastrozole for Breast Cancer. Completed, enrolled 71 participants across 1 site.

Detailed Summary

Background: Identification of new biomarkers with potential predictive and prognostic role has contributed unequivocally to breast cancer treatment. Although traditionally endocrine therapy is based on hormonal receptors status (estrogen - ER and progesterone- PR), some patients become hormone resistant. In order to identify a possible profile associated to hormonal resistance, some biomarkers have been assessed after short period primary hormone therapy (HT). Objectives: To compare the expression of Ki-67, Bcl2, Bax, Bak, ER and e PR in postmenopausal women with ER positive invasive ductal carcinomas (IDC), prior and after tamoxifen and anastrozole in short term hormone therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesBrazil
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 19, 2009
Enrollment StartApr 1, 2005
Primary CompletionJul 1, 2007
Study CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.6 years ago

Interventions

Anastrozoledrug

Tamoxifen 20mg and anastrozole 1 mg